Today: 16 March 2026
Subscribe
Browse Category

Stock Market 23 January 2026

Microsoft stock price jumps nearly 4% — what Wall Street is watching before next week’s earnings

Microsoft stock price jumps nearly 4% — what Wall Street is watching before next week’s earnings

Microsoft shares rose 3.8% to $468.31 Friday, lifting its market value to about $3.85 trillion as the broader market stayed flat. The move came despite a lingering Microsoft 365 outage, which the company said was resolved after reports peaked at over 15,000. Investors are watching next week’s tech earnings and the Federal Reserve decision for further direction.
23 January 2026
···
Nvidia stock gains on China H200 chip order report — what moves NVDA next

Nvidia stock gains on China H200 chip order report — what moves NVDA next

Nvidia shares closed up 1.5% at $187.53 after reports that Chinese regulators told Alibaba and others to prepare orders for H200 AI chips. U.S. officials have approved H200 exports to China with strict conditions, while Beijing has signaled “in-principle” approval for major tech firms. Uncertainty remains after Chinese customs blocked earlier H200 shipments. Nvidia reports earnings Feb. 25.
23 January 2026
···
Why IREN stock price is jumping today: Feb. 5 earnings set, 2x short ETF launches

Why IREN stock price is jumping today: Feb. 5 earnings set, 2x short ETF launches

IREN Limited shares jumped 7.2% to $56.04 Friday on heavy volume ahead of its Feb. 5 earnings release. The company recently disclosed a $9.7 billion Microsoft deal and aims for $3.4 billion in AI cloud revenue by late 2026. Tradr launched a leveraged ETF offering -200% of IREN’s daily move. Bitcoin traded near $89,255, with IREN’s rally seen as stock-specific.
23 January 2026
···
Tesla stock slips after Autopilot is dropped in U.S., Canada as robotaxi push meets earnings week

Tesla stock slips after Autopilot is dropped in U.S., Canada as robotaxi push meets earnings week

Tesla shares slipped 0.1% to $448.96 late Friday after the company dropped its standard Autopilot package for new U.S. and Canadian buyers. Starting Feb. 14, only a $99-per-month Full Self-Driving (Supervised) subscription will be offered. New vehicles now include just traffic-aware cruise control. Investors await Tesla’s Jan. 28 earnings and updates on software adoption and robotaxi progress.
23 January 2026
···
Critical Metals (CRML) stock jumps 10% as Saudi rare-earth talks resurface in filing

Critical Metals (CRML) stock jumps 10% as Saudi rare-earth talks resurface in filing

Critical Metals shares surged about 10% Friday after a filing disclosed a non-binding Saudi MoU and four non-binding offtake term sheets tied to its Tanbreez project. The stock closed at $20.34, up $1.88, with volume over 39 million shares. Traders are watching for binding contracts and further disclosures. The company holds a 42% stake in Tanbreez and aims to expand rare-earth processing.
23 January 2026
·
IBM stock slides in afternoon trade as investors brace for earnings and fresh security news

IBM stock slides in afternoon trade as investors brace for earnings and fresh security news

IBM shares fell 1.1% to $291.51 Friday, underperforming other tech giants as traders braced for next week’s earnings and 2026 guidance. IBM Consulting announced a new “quantum-safe” security partnership, while analysts highlighted renewed software growth and the pending $11 billion Confluent deal. The company reports Q4 results on Jan. 28.
23 January 2026
···
Applied Digital (APLD) stock jumps nearly 9% on Delta Forge AI data center build — what to watch next

Applied Digital (APLD) stock jumps nearly 9% on Delta Forge AI data center build — what to watch next

Applied Digital shares rose about 9% to $37.90 Friday after breaking ground on its Delta Forge 1 AI data center campus in Louisiana, designed for 430 megawatts of utility power. A Roth note expects a major tenant lease at the site within months. The company aims for initial operations by mid-2027. Investors are watching for a signed lease and financing details.
23 January 2026
···
SLB stock price swings after earnings beat, dividend hike and Venezuela signals

SLB stock price swings after earnings beat, dividend hike and Venezuela signals

SLB reported Q4 adjusted earnings of 78 cents per share, beating forecasts, and raised its dividend by 3.5% to $0.295. Shares rose 0.3% to $49.47 after early gains faded. The company set 2026 revenue guidance up to $37.7 billion and plans to return over $4 billion to shareholders. CEO Olivier Le Peuch cited rising customer interest in Venezuela but said expansion depends on licenses and payment terms.
23 January 2026
···
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
Maase stock jumps on Huazhi AI acquisition plan — what MAAS investors watch next

Maase stock jumps on Huazhi AI acquisition plan — what MAAS investors watch next

Maase Inc shares surged 7.8% to $6.05 after announcing its $157.1 million acquisition of Times Good Limited, adding China’s Huazhi Group. The deal includes 87.4 million new shares and $26 million cash, with sellers facing a 60-month lock-up. Maase’s stock hit a 52-week high of $6.95 before paring gains. The share portion is priced at $1.50, well below Friday’s close, raising volatility concerns.
23 January 2026
·
Life360 stock jumps 22% as record Q4 user growth lifts outlook ahead of March results

Life360 stock jumps 22% as record Q4 user growth lifts outlook ahead of March results

Life360 shares jumped 22% Friday after the company reported record Q4 user and subscriber growth and raised its 2025 revenue and adjusted EBITDA forecasts. The stock reached $66.90 in afternoon trading, up $12.09. Global monthly active users rose to 95.8 million, with 2.8 million paying circles. Full-year results and 2026 guidance are set for release March 2.
23 January 2026
···
Applied Digital (APLD) stock jumps on 430-MW Delta Forge AI campus build; location due in February

Applied Digital (APLD) stock jumps on 430-MW Delta Forge AI campus build; location due in February

Applied Digital shares rose 9.8% to $38.13 Friday after the company announced it broke ground on a new AI data center campus, Delta Forge 1, in the southern U.S. The facility targets 430 MW of utility power and aims to start operations by mid-2027. Investors pressed for tenant and location details; the CEO said the site will be revealed in February. No tenants have been named.
23 January 2026
···
Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue shares rose 0.1% to $17.77 Friday as investors await a Jan. 29 shareholder vote on its proposed sale to Kimberly-Clark. The deal would give Kenvue holders $3.50 in cash and 0.14625 Kimberly-Clark shares per Kenvue share. Institutional Shareholder Services recommended approval but cited litigation risks. Trading volume has surged ahead of the vote.
23 January 2026
···
Amphenol stock slips as Wall Street waits for earnings next week

Amphenol stock slips as Wall Street waits for earnings next week

Amphenol shares fell about 0.9% to $151.14 Friday afternoon as investors awaited its quarterly report due January 28. Trading volume was below average, with focus on the integration of the recently acquired CommScope connectivity business. The company expects the deal to boost adjusted profits by 2026. Broader U.S. markets were mixed, with the Dow down and S&P 500 near flat.
23 January 2026
··
1 … 366 367 368 369 370 … 1,351

Stock Market Today

  • JNJ's Bladder Cancer Therapy Erda-iDRS Hits Primary Safety Endpoint in Early-Stage Trial
    March 16, 2026, 2:59 PM EDT. Johnson & Johnson's (JNJ) investigational bladder cancer treatment, Erda-iDRS, met its primary safety endpoint in a Phase I study targeting non-muscle-invasive bladder cancer (NMIBC) with FGFR gene alterations, found in up to 70% of intermediate-risk and 40% of high-risk patients. The localized drug-delivery system releases erdafitinib directly into the bladder, limiting systemic side effects. Results showed an 89% complete response (CR) rate in intermediate-risk patients, with median CR duration around 18 months. High-risk patients saw median recurrence-free survival of 20 months and 83% survival at 12 months. The therapy was generally well-tolerated with mild to moderate adverse effects and no dose-limiting toxicities. Shares of JNJ rose 36.3% over six months, outperforming the 17.2% industry gain, as the company prepares for further development steps.
Go toTop